Microbiologic Findings in a Cohort of Patients with Erythema Migrans
by
, and
Eva Ružić-Sabljić
1,*, 
Vera Maraspin
2,
Petra Bogovič
2,
Tereza Rojko
2,
Katarina Ogrinc
2,
Martina Jaklič
3 and
Franc Strle
2,3 1
Institute of Microbiology and Immunology, Medical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia
2
Department of Infectious Diseases, University Medical Centre Ljubljana, 1525 Ljubljana, Slovenia
3
Centre for Clinical Research, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
*
Author to whom correspondence should be addressed.
Microorganisms 2024, 12(1), 185; https://doi.org/10.3390/microorganisms12010185
Submission received: 28 November 2023
/
Revised: 9 January 2024
/
Accepted: 12 January 2024
/
Published: 17 January 2024
(This article belongs to the Special Issue Borreliosis and Other Tick-Borne Diseases in the Northern and Southern Hemispheres)
Abstract
:Erythema migrans (EM) is the initial and the most frequent clinical manifestation of Lyme borreliosis (LB). Herein, we report on the capacity of culture and serology for the demonstration of Borrelia infection in a cohort of 292 patients diagnosed with typical EM at a single medical center. The median duration of EM at diagnosis was 12 days, and the largest diameter was 16 cm; 252 (86.3%) patients presented with solitary EM, whereas 40 (13.7%) had multiple EM. A total of 95/292 (32.5%) patients had positive IgM, and 169 (57.9%) had positive IgG serum antibodies; the Borrelia isolation rate was 182/292 (62.3%). The most frequent species by far was B. afzelii (142/148, 95.9%) while B. garinii (2.7%) and B. burgdorferi s.s. (1.4%) were rare. IgM seropositivity was associated with a younger age, multiple EM and the absence of underlying chronic illness; IgG seropositivity was associated with the duration of EM at diagnosis, the diameter of the EM, having had a previous episode of LB and the absence of symptoms at the site of the EM. Furthermore, the Borrelia isolation rate was statistically significantly lower in patients with positive Borrelia IgM antibodies. Although microbiologic analyses are not needed for the diagnosis of typical EM, they enable insights into the etiology and dynamics of the immune response in the course of early LB.
1. Introduction
Lyme borreliosis (LB) is the most common tick-borne disease in the Northern Hemisphere. It is caused by several species of Borrelia burgdorferi sensu lato complex (Lyme Borrelia). All Borrelia species use vertebrates as their reservoir hosts and ticks of the Ixodidae complex as vectors for transmission [1], but only some of them are associated with disease in humans. In Europe, LB is typically caused by Borrelia afzelii, Borrelia garinii, Borrelia bavariensis, Borrelia burgdorferi sensu stricto and Borrelia spielmanii, while in North America, B. burgdorferi sensu stricto is a highly predominant etiologic agent of the disease in humans [2,3].
The first sign of LB is usually an expanding skin lesion, erythema migrans (EM), that appears at the site of an infected tick bite within days to weeks after the bite [3]. However, since tick bites are typically painless and may occur at body sites that are difficult to perceive, several patients do not recall a tick bite. Nevertheless, if untreated, Borrelia may disseminate from the skin to other organ systems, including the nervous system, joints, or heart [2,3].
Erythema migrans is the most common clinical manifestation of LB. It is the only clinical manifestation that is sufficiently distinctive to allow a clinical diagnosis in the absence of a positive laboratory test. The three essential bases for a diagnosis of EM are (i) compatible information on the course of the skin lesion; (ii) recognition of the characteristic appearance; and (iii) an epidemiologic link (a person who lives in or has recently traveled to areas endemic for LB) [4]. Microbiologic findings are essential for the diagnosis of atypical EM skin lesions and all other manifestations of LB. However, in patients with typical EM, microbiological diagnosis is important for the research of the etiology of the skin disorder, as well as for monitoring the development and dynamics of the immune response in the course of early disease [2,3]. Herein, we report on the assessment of the capacity of culture and serology for demonstrations of Borrelia infection in a cohort of patients diagnosed with typical EM at a single medical center.
2. Materials and Methods
2.1. Patients
All patients with typical EM, diagnosed in 2013 at the LB Outpatient Clinic of the Department of Infectious Diseases, University Medical Centre Ljubljana, Slovenia, who had not received antibiotics before the examination; who were tested for the presence of Borrelia antibodies in serum; who had a skin biopsy and culture of the specimen for the presence of Borrelia performed; and who were examined by the authors of this paper, were included in this study.
Epidemiologic and clinical data were obtained prospectively using a questionnaire.
2.2. Definitions
EM was defined as an expanding erythematous skin lesion, with or without central clearing, that developed days to weeks after a tick bite or exposure to ticks and had a diameter ≥ 5 cm. If <5 cm in diameter, a history of a tick bite, a delay in the appearance of at least 2 days and an expanding rash at the bite site were required for a diagnosis of EM. Multiple EM was defined as the presence of ≥2 skin lesions, at least one of which fulfilled the size criteria (≥5 cm) for solitary EM [5].
2.3. Microbiological Analyses
To confirm Borrelia infection, all patients were tested for the presence of specific IgM and IgG antibodies in serum as well as for the presence of Borrelia in a skin biopsy specimen. All microbiological analyses were performed at the Institute of Microbiology and Immunology, Medical Faculty, University of Ljubljana.
2.3.1. Serological Evaluation
Specific IgM and IgG antibodies were examined in blood samples via a commercially available chemiluminescence (CLIA) test produced by DiaSorin, Italy. Recombinant antigens OspC and VlsE were included in the test to capture specific IgM, and VlsE only was used to capture specific IgG antibodies. The results were reported as qualitative and quantitative (antibody units per mL, AU/mL) according to the manufacturer’s recommendation [6].
2.3.2. Borrelia Cultivation and Typing
To test for the presence of Borrelia in skin, a 3 mm punch biopsy was obtained from the expanding edge of the EM after local anesthesia, as reported elsewhere [7]. The skin biopsy specimen was immediately inoculated into a 10 mL tube with a modified Kelly-Pettenkofer (MKP) medium. The tubes were incubated at 33 °C for 9 weeks, weekly subcultured and checked for live spirochetes under dark-field microscopy [8]. Isolated Borrelia strains were characterized at the species level based on MluI-large restriction fragment polymorphism (MluI-LRFP) [9].
2.4. Statistical Analysis
Continuous variables were summarized using median values and interquartile ranges (IQRs), and discrete variables were summarized using counts and percentages. The Shapiro–Wilk test was used to examine the normality assumption of the continuous variables. Differences between groups were analyzed with independent-sample t-tests for continuous variables, and Fisher’s exact tests or Pearson’s Chi-square test were used for categorical variables.
To assess the association of the presence of microbiologic parameters (presence of Borrelia IgM antibodies in serum, presence of Borrelia IgG antibodies in serum, isolation of Borrelia from skin) and several clinical parameters (sex, age, underlying chronic illness, previous LB, tick bite, duration of EM at diagnosis, diameter of EM at diagnosis, multiple EM, symptoms at the site of EM, constitutional symptoms), we estimated three separate logistic regression models with individual microbiologic parameters representing dependent variables. p values < 0.05 were considered statistically significant. The data were analyzed using SPSS version 25.0 (SPSS Inc., Chicago, IL, USA).
3. Results
In 2013, 520 adult patients with typical EM were diagnosed at our LB Outpatient Clinic, Ljubljana, Slovenia. Of these, 292 (141 females and 151 males) fulfilled all inclusion criteria (had not received antibiotics before the examination, were tested for the presence of Borrelia antibodies in serum, had a skin biopsy and culture of the skin specimen for the presence of Borrelia performed, and were examined by the authors of this paper) and were enrolled in the present study. The basic clinical findings for these 292 patients are depicted in Table 1. All 292 patients had typical EM; 144 (49.3%) of them recalled a tick bite at the site of a later EM. The median duration of EM at diagnosis was 12 days, and the largest diameter of the lesion was 16 cm. Of the 292 patients, 252 (86.3%) had solitary EM, while in 40 (13.7%) patients, more than one skin lesion was present. Nearly half of the patients reported symptoms at the site of the EM (most often mild itching, rarely local burning or pain); approximately one third had constitutional symptoms such as fatigue, headache, myalgia and/or arthralgia that newly appeared or intensified with the onset of the EM skin lesion.
Microbiologic findings are shown in Table 2. Of the 292 patients, 95 (32.5%) had positive serum IgM antibodies; in 23 (7.9%), the result was borderline, while 174 (59.6%) patients tested negative. The corresponding findings for IgG antibodies were 169 (57.9%), 25 (8.6%) and 98 (33.6%), for positive, borderline and negative results, respectively. Of the 292 patients, 195 (66.8%) were IgM- and/or IgG-seropositive.
We isolated Borrelia from the EM skin lesion in 182/292 (62.3%) patients. Borrelia growth was apparent 11 to 58 (median 24) days after skin biopsy. The distribution of days from skin biopsy to the detection of growth in culture is shown in Figure 1.
Typing was performed for the majority of isolates (148/182, 81.32%). The far most frequent species was B. afzelii (142/148, 95.9%), while B. garinii and B. burgdorferi s.s. were rare (4/148, 2.7% and 2/148, 1.4%, respectively).
As shown in Table 3, IgM seropositivity was associated with a younger age (median age of IgM-positive patients was 44 years vs. 53 years in IgM-negative/borderline patients; p < 0.001), while IgG seropositivity was positively associated with the duration of EM at diagnosis (median duration of EM in IgG-positive patients was 14 days vs. 9 days in IgG-negative/borderline patients; p = 0.001) and the diameter of the EM (median diameter of EM in IgG-positive patients was 19 cm vs. 12 cm in IgG-negative/borderline patients; p = 0.003).
Furthermore, patients with positive IgM had an underlying chronic illness less often than the IgM-negative/borderline patients (28/95, 25.9% vs. 80/187, 42.8%; p = 0.0410), but multiple EM was experienced more frequently than in IgM-negative/borderline patients (24/95, 25.3% vs. 16/187, 8.6%; p = 0.0003). Patients with positive IgG antibodies more often recalled having had a previous episode of LB (42/169, 24.8% vs. 15/123, 12.2%; p = 0.0109), and less often reported symptoms at the site of the EM skin lesion than those with negative/borderline IgG (66/169, 39.1% vs. 72/123, 58.5%; p = 0.0015). The only statistically significant finding associated with the skin culture results was that the Borrelia isolation rate was lower in patients with positive IgM than in those with negative/borderline findings (40/182, 22.5% vs. 55/110 (50%; p < 0.0001) (Table 4).
According to statistical models, age was statistically significantly associated with the presence of Borrelia IgM and IgG antibodies in serum; however, IgM seropositivity was associated with a younger age (Table 5), while IgG seropositivity was associated with older age (Table 6). Furthermore, Borrelia IgM seropositivity was statistically significantly associated with multiple EM (Table 5), while the presence of Borrelia IgG antibodies in the serum was positively associated with previous LB, the duration of EM at diagnosis and the diameter of EM at diagnosis (Table 6). Among the parameters tested for their association with the isolation of Borrelia from skin, a statistically significant association was found only for underlying chronic illness (Table 7).
4. Discussion
Our study encompassed 292 adult Slovenian patients with EM, an early and by far the most frequent manifestation of LB. None of these patients had received antibiotics before the examination; all were tested for the presence of Borrelia antibodies in their sera, had a skin biopsy and culture of the specimen for the presence of Borrelia performed and were examined by the authors of this paper. The fact that clinical and epidemiological information on these patients was obtained prospectively using a questionnaire, that all patients had a typical EM and that each of them fulfilled all pre-defined inclusion criteria enabled a rather homogeneous and large study group, well-suited for the assessment of microbiological characteristics of early LB. These characteristics had been quite extensively studied in the first two decades after the discovery of Lyme disease in the USA, but not so much during the last few decades, i.e., using more recent serological approaches. In addition, both serology and Borrelia culturing in the same patients, and the typing of the obtained isolates, were rarely performed.
Of the 292 patients, 95 (32.5%) had positive IgM Borrelia antibodies in sera and 169 (57.9%) had positive Borrelia IgG antibodies; overall, 195 (66.8%) patients were IgM- and/or IgG-positive. Thus, one third of our patients with typical EM did not have a serum Borrelia antibody response in a positive range. This is not a surprise, since it is well-known that early in the course of Borrelia infection, not all patients are seropositive [10,11]. However, it was rather unexpected that in early LB, with a median EM lesion duration of 12 days, the proportion of seropositivity was lower for IgM than for IgG antibodies. We do not have a reliable explanation for this finding; however, IgG seropositivity might be in part due to a previous Borrelia infection, either symptomatic (19.5% of our patients reported having had previous LB) or asymptomatic. The finding that, in our patients with an antecedent episode of LB, IgG antibodies were present in a higher proportion than in those without previous LB strengthens this hypothesis.
IgG seropositivity was associated with a longer duration and larger diameter of EM skin lesion at diagnosis, with information on having had a previous episode of LB and with a less frequent presence of symptoms at the site of the EM, while IgM seropositivity was associated with younger age, multiple EM and a less frequent presence of underlying illness. The associations of the duration of EM and the diameter of the skin lesion with IgG seropositivity, as well of that of multiple EM with IgM seropositivity, were predictable, while the other statistically significant associations were rather unexpected. All predictable associations were also found to be statistically significant in statistical models used in the present study, while the others—with the exception of the association of IgM seropositivity with younger age—were not.
In the present study, the Borrelia isolation rate from the skin of EM lesions was 62%, which is within the range of previously reported proportions (from 20% to almost 90%) [3,11,12]. The Borrelia recovery rate depends upon several factors. Since the number of Borrelia strains present in skin samples was found to be low, and the numbers of cultivable spirochetes and their different growth potential (which presents Borrelia’s natural make-up) in individual samples are rather unpredictable, the volume of specimen obtained is important [13,14,15]. Comparing quantitative PCR and culture, O’Rourke et al. confirmed that the number of Borrelia in culture-positive skin samples is significantly higher than in culture-negative specimens [13]. Wormser et al. enhanced the sensitivity of the culture by increasing the volume of material cultured [14]. However, the present study was not designed to assess the influence of sample volume on the Borrelia recovery rate from skin because the volume of the samples obtained with the 3 mm punch biopsy was approximately the same in all patients. Nevertheless, in the present study, several other clinical and laboratory parameters were tested for their potential association with the Borrelia skin culture results. The only statistically significant finding was that the isolation rate of Borrelia from skin was more than two times lower in patients with positive Borrelia IgM antibodies in sera than in patients with negative or borderline levels of IgM serum antibodies. However, among the parameters tested for their association with the isolation of Borrelia from skin in a statistical model, the association between Borrelia IgM seropositivity and positive Borrelia skin culture was not statistically significant. In the study of Strle and al. that compares the clinical characteristics of more than 1000 either culture-positive or -negative EM patients, the authors reported a correlation of culture positivity with older age, the location of the EM on extremities, a diameter of EM ≥ 5 cm and a time interval of >2 days between the tick bite and the EM’s appearance [16], while the only statistically significant association in our study was found for underlying chronic illness (Table 7). Some other studies also discuss the clinical features, laboratory findings and epidemiological data of erythema migrans patients [17,18,19].
Borrelia growth was detected on median day 24 after the inoculation of the skin specimen in the MKP culture medium. Since the medium was not checked for growth daily, but rather (usually) once per week, the detection time is most probably overestimated by a few days. Borrelia need time to adapt to artificial media and to multiply. It seems that the adaptation times are rather heterogeneous—in the present study, Borrelia growth was detected microscopically as early as day 11 and as late as day 58 after the inoculation of the skin specimen into the culture medium. Furthermore, it seems that the temporal occurrence does not follow a normal distribution, and that there are two main peaks: the majority of Borrelia strains multiplied sufficiently to be detected microscopically 21–27 days following the inoculation of the skin specimen into the culture medium, while several strains adapted as early as within the first 14 days (Figure 1). It is of interest that the two B. burgdorferi sensu stricto strains obtained in the present study were detected in culture rather late (4–5 weeks after inoculation), although strains of this species were reported to grow faster than strains of the other European Borrelia species that are pathogenic to humans [20]. Nevertheless, in addition to the period needed for adaptation, the time until culture positivity depends upon two main parameters: the number of Borrelia strains in the initial sample and the generation time deposited in the bacteria genome.
We do not have a reliable explanation for the negative correlation between the Borrelia isolation rate from the skin and the presence of Borrelia IgM (but not IgG) antibodies in serum (Table 4). However, low IgM seropositivity in EM patients with Borrelia isolation from skin and/or blood has been reported previously [21].
Our study revealed a pronounced predominance of B. afzelii among skin isolates (96%). This proportion was comparable or even slightly higher compared to most of the data published so far for Slovenia [9,13,22], possibly due to the fact that in the cohort of EM patients enrolled in the present study, those with clinical indications of neurologic involvement, which is often associated with B. garinii, were not included.
The strength of our study is its large and well-defined group of patients with typical EM for whom clinical and epidemiological information was obtained prospectively using a questionnaire and for whom we used exactly the same diagnostic approaches to confirm B. burgdorferi s. l. infection, including testing for the presence of Borrelia antibodies in sera and culturing the skin biopsy specimen for the presence of Borrelia. Our results, however, apply to adult patients but not necessarily to children, and to early LB caused by B. afzelii but not to other Borrelia species causing LB in humans.
5. Conclusions
In the group of 292 adult Slovenian patients with typical EM and median skin lesion duration of 12 days, 33% of patients had positive IgM and 58% had positive IgG antibodies, while the Borrelia isolation rate from the skin of the EM lesions was 62%. Borrelia growth was detected 11 to 58 (median 24) days after skin biopsy; 96% of the isolates were B. afzelii. IgM seropositivity was associated with younger age and multiple EM, while IgG seropositivity was associated with the duration of EM as well as the diameter of the EM at diagnosis, and with having had a previous episode of LB. The only statistically significant finding associated with the skin culture results was the lower Borrelia isolation rate in patients with positive serum IgM antibodies.
Author Contributions
Conceptualization, E.R.-S. and F.S.; methodology, E.R.-S., F.S. and M.J.; validation, F.S., E.R.-S., and V.M.; formal analysis, E.R.-S., F.S. and M.J.; investigation, E.R.-S., F.S., P.B. and K.O.; resources, E.R.-S., F.S., P.B., V.M., T.R., M.J. and K.O.; data curation, V.M. and E.R.-S.; writing—original draft preparation, F.S. and E.R.-S.; writing—review and editing, F.S., E.R.-S., P.B., V.M., T.R., M.J. and K.O.; supervision, F.S. and E.R.-S.; funding acquisition, E.R.-S. All authors have read and agreed to the published version of the manuscript.
Funding
This research was partly funded by the Slovenian Research Agency, grant numbers P3-0083 and P3-0296. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Data Availability Statement
All the relevant data are included in the manuscript in an aggregated format.
Acknowledgments
The authors would like to thank the staff and patients at the Department of Infectious Diseases, University Medical Centre Ljubljana, and the staff at the Laboratory for Diagnostics of Borreliosis and Leptospirosis, Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana.
Conflicts of Interest
F.S. served on the scientific advisory board for Roche on Lyme disease serological diagnostics and on the scientific advisory board for Pfizer on a Lyme disease vaccine, and is an unpaid member of the steering committee of the ESCMID Study Group on Lyme Borreliosis/ESGBOR. The other authors declare no conflicts of interest.
References
- Wolcott, K.A.; Margos, G.; Fingerle, V.; Becker, N.S. Host association of Borrelia burgdorferi sensu lato: A review. Ticks Tick-Borne Dis. 2021, 12, 101766. [Google Scholar] [CrossRef] [PubMed]
- Radolf, J.D.; Strle, K.; Lemieux, J.E.; Strle, F. Lyme Disease in Humans. Curr. Issues Mol. Biol. 2021, 42, 333–384. [Google Scholar] [CrossRef]
- Stanek, G.; Strle, F. Lyme borreliosis-from tick bite to diagnosis and treatment. FEMS Microbiol. Rev. 2018, 42, 233–258. [Google Scholar] [CrossRef]
- van den Wijngaard, C.C.; Hofhuis, A.; Simoes, M.; Rood, E.; van Pelt, W.; Zeller, H.; Van Bortel, W. Surveillance perspective on Lyme borreliosis across the European Union and European Economic Area. Eurosurveillance 2017, 22, 30569. [Google Scholar] [CrossRef] [PubMed]
- Stanek, G.; Fingerle, V.; Hunfeld, K.P.; Jaulhac, B.; Kaiser, R.; Krause, A.; Kristoferitsch, W.; O’Connell, S.; Ornstein, K.; Strle, F.; et al. Lyme borreliosis: Clinical case definitions for diagnosis and management in Europe. Clin. Microbiol. Infect. 2011, 17, 69–79. [Google Scholar] [CrossRef]
- Cerar, T.; Ruzic-Sabljic, E.; Cimperman, J.; Strle, F. Comparison of immunofluorescence assay (IFA) and LIAISON in patients with different clinical manifestations of Lyme borreliosis. Wien. Klin. Wochenschr. 2006, 118, 686–690. [Google Scholar] [CrossRef]
- Maraspin, V.; Bogovic, P.; Rojko, T.; Ogrinc, K.; Ruzic-Sabljic, E.; Strle, F. Early Lyme Borreliosis in Patients Treated with Tumour Necrosis Factor-Alfa Inhibitors. J. Clin. Med. 2019, 8, 1857. [Google Scholar] [CrossRef]
- Busch, U.; Teufel, C.H.; Boehmer, R.; Wilske, B.; Preac-Mursic, V. Molecular characterization of Borrelia burgdorferi sensu lato strains by pulsed-field gel electrophoresis. Electrophoresis 1995, 16, 744–747. [Google Scholar] [CrossRef] [PubMed]
- Ruzic-Sabljic, E.; Zore, A.; Strle, F. Characterization of Borrelia burgdorferi sensu lato isolates by pulsed-field gel electrophoresis after MluI restriction of genomic DNA. Res. Microbiol. 2008, 159, 441–448. [Google Scholar] [CrossRef]
- Leeflang, M.M.; Ang, C.W.; Berkhout, J.; Bijlmer, H.A.; Van Bortel, W.; Brandenburg, A.H.; Van Burgel, N.D.; Van Dam, A.P.; Dessau, R.B.; Fingerle, V.; et al. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: A systematic review and meta-analysis. BMC Infect. Dis. 2016, 16, 140. [Google Scholar] [CrossRef]
- Guerin, M.; Shawky, M.; Zedan, A.; Octave, S.; Avalle, B.; Maffucci, I.; Padiolleau-Lefevre, S. Lyme borreliosis diagnosis: State of the art of improvements and innovations. BMC Microbiol. 2023, 23, 204. [Google Scholar] [CrossRef] [PubMed]
- Aguero-Rosenfeld, M.E.; Wang, G.; Schwartz, I.; Wormser, G.P. Diagnosis of lyme borreliosis. Clin. Microbiol. Rev. 2005, 18, 484–509. [Google Scholar] [CrossRef] [PubMed]
- O’Rourke, M.; Traweger, A.; Lusa, L.; Stupica, D.; Maraspin, V.; Barrett, P.N.; Strle, F.; Livey, I. Quantitative detection of Borrelia burgdorferi sensu lato in erythema migrans skin lesions using internally controlled duplex real time PCR. PLoS ONE 2013, 8, e63968. [Google Scholar] [CrossRef] [PubMed]
- Wormser, G.P.; Bittker, S.; Cooper, D.; Nowakowski, J.; Nadelman, R.B.; Pavia, C. Yield of large-volume blood cultures in patients with early Lyme disease. J. Infect. Dis. 2001, 184, 1070–1072. [Google Scholar] [CrossRef]
- Stupica, D.; Lusa, L.; Maraspin, V.; Bogovic, P.; Vidmar, D.; O’Rourke, M.; Traweger, A.; Livey, I.; Strle, F. Correlation of Culture Positivity, PCR Positivity, and Burden of Borrelia burgdorferi Sensu Lato in Skin Samples of Erythema Migrans Patients with Clinical Findings. PLoS ONE 2015, 10, e0136600. [Google Scholar] [CrossRef]
- Strle, F.; Lusa, L.; Ruzic-Sabljic, E.; Maraspin, V.; Lotric Furlan, S.; Cimperman, J.; Ogrinc, K.; Rojko, T.; Videcnik Zorman, J.; Stupica, D. Clinical characteristics associated with Borrelia burgdorferi sensu lato skin culture results in patients with erythema migrans. PLoS ONE 2013, 8, e82132. [Google Scholar] [CrossRef] [PubMed]
- Eriksson, P.; Schroder, M.T.; Niiranen, K.; Nevanlinna, A.; Panelius, J.; Ranki, A. The many faces of solitary and multiple erythema migrans. Acta Derm. Venereol. 2013, 93, 693–700. [Google Scholar] [CrossRef]
- Egberts, F.; Moller, M.; Proksch, E.; Schwarz, T. Multiple erythema migrans—Manifestation of systemic cutaneous borreliosis. J. Dtsch. Dermatol. Ges. 2008, 6, 350–353. [Google Scholar] [CrossRef]
- Glatz, M.; Resinger, A.; Semmelweis, K.; Ambros-Rudolph, C.M.; Mullegger, R.R. Clinical spectrum of skin manifestations of Lyme borreliosis in 204 children in Austria. Acta Derm. Venereol. 2015, 95, 565–571. [Google Scholar] [CrossRef]
- Ruzic-Sabljic, E.; Strle, F. Comparison of growth of Borrelia afzelii, B. garinii, and B. burgdorferi sensu stricto in MKP and BSK-II medium. Int. J. Med. Microbiol. 2004, 294, 407–412. [Google Scholar] [CrossRef]
- Maraspin, V.; Ogrinc, K.; Rojko, T.; Bogovic, P.; Ruzic-Sabljic, E.; Kastrin, A.; Wormser, G.P.; Strle, F. Characteristics of spirochetemic patients with a solitary erythema migrans skin lesion in Europe. PLoS ONE 2021, 16, e0250198. [Google Scholar] [CrossRef] [PubMed]
- Ogrinc, K.; Kastrin, A.; Lotric-Furlan, S.; Bogovic, P.; Rojko, T.; Maraspin, V.; Ruzic-Sabljic, E.; Strle, K.; Strle, F. Colocalization of radicular pain and erythema migrans in patients with Bannwarth’s syndrome suggests a direct spread of borrelia into the central nervous system. Clin. Infect. Dis. 2021, 75, 81–87. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Days from skin biopsy to positive culture.
Table 1.
Basic epidemiologic and clinical data on 292 patients with erythema migrans.
| Female Sex | 141 (48.3) |
| Age (years) | 51 (40–60) |
| Underlying chronic illness | 108 (37.0) |
| Previous LB | 57 (19.5) |
| Tick bite * | 144 (49.3) |
| Duration of EM at diagnosis | 12 (4–29) |
| Diameter of EM at diagnosis | 16 (10–24) |
| Multiple EM | 40 (13.7) |
| Symptoms at the site of EM | 138 (47.3) |
| Constitutional symptoms | 99 (33.9) |
Data are number (%) or median (IQR); LB, Lyme borreliosis; EM, erythema migrans; * at the site of the EM.
Table 2.
Microbiologic findings in patients with erythema migrans at diagnosis.
| Borrelia Antibodies in Serum | |
| IgM-positive | 95 (32.5) |
| borderline | 23 (7.9) |
| negative | 174 (59.6) |
| IgM levels: all patients | 13.2 (7.3–32.4) |
| seropositive patients | 54.3 (32.4–156.0) |
| IgG-positive | 169 (57.9) |
| borderline | 25 (8.6) |
| negative | 98 (33.6) |
| IgG levels: all patients * | 23.3 (7.4–75.0) |
| seropositive patients ** | 56.3 (28.0–147.6) |
| IgM- and/or IgG-positive | 195 (66.8) |
| Isolation of Borrelia burgdorferi sensu lato from skin | |
| Isolation | 182 (62.3%) |
| Time from skin biopsy to positive culture (days) | 24 (13–26) range 11–58 |
| Borrelia species *** | |
| B. afzelii | 142 (95.9) |
| B. garinii | 4 (2.7) |
| B. burgdorferi s.s. | 2 (1.4) |
| IgM- and/or IgG- and/or Borrelia culture-positive | 261 (89.4) |
Data are number (%) or median (IQR); * information available for 286/292 patients; ** information available for 168/169 patients; *** of 182 isolates, 148 have been typed.
Table 3.
Association of IgM seropositivity, IgG seropositivity and Borrelia skin culture positivity with patients’ age, duration of EM at diagnosis and diameter of EM at diagnosis.
Table 3.
Association of IgM seropositivity, IgG seropositivity and Borrelia skin culture positivity with patients’ age, duration of EM at diagnosis and diameter of EM at diagnosis.
| Parameter | All Patients | IgM-pos | IgM-neg * | p | IgG-pos | IgG-neg * | p | Skin Culture-pos | Skin Culture-neg | p |
|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 51 (40–60) | 44 (34–57) | 53 (42–62) | <0.001 | 52 (40–61) | 50 (38–59) | 0.184 | 52 (40–61) | 50 (38–60) | 0.408 |
| Duration of EM at diagnosis | 12 (4–29) | 11 (5–28) | 12 (4–30) | 0.900 | 14 (6–30) | 9 (4–21) | 0.001 | 9 (4–23) | 14 (7–31) | 0.095 |
| Diameter of EM at diagnosis | 16 (10–24) | 18 (10–26) | 15 (10–23) | 0.606 | 19 (13–26) | 12 (8–18) | 0.003 | 15 (10–24) | 17 (12–24) | 0.853 |
EM, erythema migrans; pos, positive; neg *, negative or borderline; boldface is used for p-values < 0.05.
Table 4.
Association of IgM seropositivity, IgG seropositivity and Borrelia skin culture positivity with discrete clinical and laboratory parameters.
Table 4.
Association of IgM seropositivity, IgG seropositivity and Borrelia skin culture positivity with discrete clinical and laboratory parameters.
| Number of Patients No = 292 | IgM-pos N=95 | IgM-neg * N=187 | p Value | IgG-pos N=169 | IgG-neg * N=123 | p Value | Isolation-pos N=182 | Isolation-neg No=110 | p Value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Female sex | 141 (48.3%) | 45 (47.4%) | 96 (51.3%) | 0.6142 | 73 (51.8%) | 68 (55.3%) | 0.0545 | 85 (46.7%) | 56 (50.9%) | 0.5646 |
| Underlying illness | 108 (37.0%) | 28 (25.9%) | 80 (42.8%) | 0.0410 | 61 (56.6%) | 47 (38.2%) | 0.8048 | 62 (57.4%) | 42 (38.2%) | 0.4767 |
| Previous LB | 57 (19.5%) | 16 (28.1%) | 41 (21.9%) | 0.0772 | 42 (24.8%) | 15 (12.2%) | 0.0109 | 40 (22.0%) | 17 (15.5%) | 0.2266 |
| Tick bite ** | 144 (49.3%) | 41 (43.2%) | 103 (55.1%) | 0.3966 | 78 (46.2%) | 66 (53.7%) | 0.2510 | 93 (51.1%) | 51 (46.4%) | 0.5070 |
| Multiple EM | 40 (13.7%) | 24 (25.3%) | 16 (8.6%) | 0.0003 | 28 (16.6%) | 12 (9.8%) | 0.1338 | 22 (12.1%) | 18 (16.4%) | 0.3931 |
| Symptoms at the site of EM | 138 (47.3%) | 41 (43.2%) | 97 (51.9%) | 0.2086 | 66 (39.1%) | 72 (58.5%) | 0.0015 | 87 (47.8%) | 51 (46.4%) | 0.9064 |
| Constitutional symptoms | 99 (33.9%) | 33 (34.7%) | 66 (35.3%) | 0.9686 | 59 (34.9%) | 40 (32.5%) | 0.7634 | 64 (35.2%) | 35 (31.8%) | 0.6471 |
| IgM pos | 95 (32.5%) | / | / | / | 61 (36.1%) | 34 (27.6%) | 0.1628 | 40 (22.5%) | 55 (50%) | <0.0001 |
| IgG pos | 169 (57.9%) | 61 (64.2%) | 108 (57.8%) | 0.3590 | / | / | / | 105 (57.7%) | 64 (58.2%) | 0.9679 |
| Skin culture pos | 182 (62.3%) | 60 (63.2%) | 122 (65.2%) | 0.8307 | 105 (62.1%) | 77 (62.6%) | 0.9679 | / | / | / |
pos, positive; neg *, negative or borderline; neg, negative; LB, Lyme borreliosis; EM, erythema migrans; boldface is used for p-values < 0.05; ** at the site of the EM skin lesion.
Table 5.
Association between clinical parameters and the presence of Borrelia IgM antibodies in serum.
Table 5.
Association between clinical parameters and the presence of Borrelia IgM antibodies in serum.
| B | Wald | df | Sig. | |
|---|---|---|---|---|
| Intercept | 2.256 | 9.290 | 1 | 0.002 |
| Sex | 0.154 | 0.253 | 1 | 0.615 |
| Age | −0.040 | 11.549 | 1 | 0.001 |
| Underlying chronic illness | 0.037 | 0.012 | 1 | 0.914 |
| Previous LB | 0.109 | 0.077 | 1 | 0.781 |
| Tick bite * | −0.123 | 0.160 | 1 | 0.689 |
| Multiple EM | −1.183 | 7.212 | 1 | 0.007 |
| Symptoms at the site of EM | 0.098 | 0.311 | 1 | 0.752 |
| Constitutional symptoms | 0.002 | 0.329 | 1 | 0.995 |
| Duration of EM at diagnosis | 0.003 | 0.158 | 1 | 0.691 |
| Diameter of EM at diagnosis | 0.002 | 0.034 | 1 | 0.853 |
| IgG-pos | −0.536 | 2.608 | 1 | 0.106 |
| Skin culture-pos | −0.21 | 0.453 | 1 | 0.501 |
LB, Lyme borreliosis; EM, erythema migrans; pos, positive; boldface is used for p-values < 0.05; * at the site of the EM skin lesion.
Table 6.
Association between clinical parameters and the presence of Borrelia IgG in serum.
| B | Wald | df | Sig. | |
|---|---|---|---|---|
| Intercept | −0.670 | 0.890 | 1 | 0.345 |
| Sex | −0.558 | 3.679 | 1 | 0.055 |
| Age | 0.029 | 6.508 | 1 | 0.011 |
| Underlying chronic illness | −0.558 | 2.956 | 1 | 0.086 |
| Previous LB | 1.146 | 8.554 | 1 | 0.003 |
| Tick bite * | 0.076 | 0.064 | 1 | 0.800 |
| Multiple EM | −0.725 | 2.285 | 1 | 0.131 |
| Duration of EM at diagnosis | 0.025 | 8.405 | 1 | 0.004 |
| Diameter of EM at diagnosis | 0.028 | 5.773 | 1 | 0.016 |
| Symptoms at the site of EM | −0.680 | 5.344 | 1 | 0.021 |
| Constitutional symptoms | −0.016 | 0.002 | 1 | 0.960 |
| IgM-pos | −0.599 | 3.192 | 1 | 0.074 |
| Skin culture-pos | 0.390 | 1.626 | 1 | 0.202 |
LB, Lyme borreliosis; EM, erythema migrans; pos, positive; boldface is used for p-values < 0.05; * at the site of the EM skin lesion.
Table 7.
Association between clinical parameters and the isolation of Borrelia burgdorferi sensu lato from skin.
Table 7.
Association between clinical parameters and the isolation of Borrelia burgdorferi sensu lato from skin.
| B | Wald | df | Sig. | |
|---|---|---|---|---|
| Intercept | −0.633 | 0.919 | 1 | 0.338 |
| Sex | −0.181 | 0.426 | 1 | 0.514 |
| Age | 0.018 | 2.820 | 1 | 0.093 |
| Underlying chronic illness | −0.684 | 5.003 | 1 | 0.025 |
| Previous LB | 0.503 | 1.832 | 1 | 0.176 |
| Tick bite * | 0.260 | 0.864 | 1 | 0.353 |
| Multiple EM | 0.330 | 0.582 | 1 | 0.446 |
| Symptoms at the site of EM | −0.105 | 0.136 | 1 | 0.712 |
| Constitutional symptoms | 0.242 | 0.622 | 1 | 0.430 |
| Duration of EM at diagnosis | −0.005 | 0.532 | 1 | 0.466 |
| Diameter of EM at diagnosis | 0.003 | 0.069 | 1 | 0.793 |
| IgM-pos | −0.228 | 0.527 | 1 | 0.468 |
| IgG-pos | 0.423 | 1.968 | 1 | 0.161 |
LB, Lyme borreliosis; EM, erythema migrans; pos, positive; boldface is used for p-values < 0.05; * at the site of the EM skin lesion.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Ružić-Sabljić, E.; Maraspin, V.; Bogovič, P.; Rojko, T.; Ogrinc, K.; Jaklič, M.; Strle, F. Microbiologic Findings in a Cohort of Patients with Erythema Migrans. Microorganisms 2024, 12, 185. https://doi.org/10.3390/microorganisms12010185
AMA Style
Ružić-Sabljić E, Maraspin V, Bogovič P, Rojko T, Ogrinc K, Jaklič M, Strle F. Microbiologic Findings in a Cohort of Patients with Erythema Migrans. Microorganisms. 2024; 12(1):185. https://doi.org/10.3390/microorganisms12010185
Chicago/Turabian StyleRužić-Sabljić, Eva, Vera Maraspin, Petra Bogovič, Tereza Rojko, Katarina Ogrinc, Martina Jaklič, and Franc Strle. 2024. "Microbiologic Findings in a Cohort of Patients with Erythema Migrans" Microorganisms 12, no. 1: 185. https://doi.org/10.3390/microorganisms12010185
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
